TVRD — Tvardi Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
$1.83
+$0.08 (+4.87%)
Tvardi Therapeutics, Inc. (TVRD) is a biotechnology company listed on NASDAQ. It is led by Imran Alibhai Ph.D., based in 3 Sugar Creek Center Boulevard, Sugar Land, TX, United States, 77478. Tvardi Therapeutics, Inc. operates as a biotechnology company that develops medicines for cancer, chronic inflammation diseases, and fibrosis diseases. It develops inhibitors of STAT3, a molecule implicated in the initiation and progression of cancer and fibrosis. Its pipeline includes TTI-101, a small-molecule inhibitor of signal transducers and activators of transcription; and TTI-109, a STAT3 inhibitor for clinical use, including tolerability, bioavailability, and potency. Tvardi Therapeutics, Inc. was incorporated in 2017 and is based in Sugar Land, Texas.
Net income was -$10.9M.
Use this TVRD page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the TVRD quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the TVRD SEC filings page. Lician reads the product cache first so this HTML stays unique to Tvardi Therapeutics, Inc. even when a live quote feed is slow.
About Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc. operates as a biotechnology company that develops medicines for cancer, chronic inflammation diseases, and fibrosis diseases. It develops inhibitors of STAT3, a molecule implicated in the initiation and progression of cancer and fibrosis. Its pipeline includes TTI-101, a small-molecule inhibitor of signal transducers and activators of transcription; and TTI-109, a STAT3 inhibitor for clinical use, including tolerability, bioavailability, and potency. Tvardi Therapeutics, Inc. was incorporated in 2017 and is based in Sugar Land, Texas.
TVRD Key Statistics
Market Cap
$0.00M
Volume
77,061
Previous Close
$1.78
Day Range
$1.78 – $1.89
EPS
-$15.53
Revenue
$7.14M
Net Income
-$70.87M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-66.0%
Profit Margin
-993.0%
TVRD Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $7.14M | $20.97M | $41.87M | $23.03M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$70.87M | -$118.51M | -$85.47M | -$88.44M |
| EPS (Diluted) | -$15.53 | -$26.26 | -$19.12 | -$1.74 |
Total Assets
$43.83M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$37.90M
Operating Cash Flow
-$60.92M
Free Cash Flow
$0.00
Tvardi Therapeutics, Inc. Company Information
- CEO & Director
- Imran Alibhai Ph.D.
- Headquarters
- 3 Sugar Creek Center Boulevard, Sugar Land, TX, United States, 77478
- Website
- tvarditherapeutics.com
- Phone
- 832-413-1362
- IPO / Founded
- 2014-01-31
- Sector
- Healthcare
- Industry
- Biotechnology